Effect of HIV-1 exposure and antiretroviral treatment strategies in HIV-infected children on immunogenicity of vaccines during infancy

AIDS

Volumn 28, Issue 4, 2014, Pages 531-541

  Simani, Omphile E ^a   Izu, Alane ^a   Violari, Avy ^c   Cotton, Mark F ^d   Van Niekerk, Nadia ^a   Adrian, Peter V ^a,b   Madhi, Shabir A ^a,b,e  

^a NATIONAL RESEARCH FOUNDATION   (South Africa)

^b UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^c UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^d STELLENBOSCH UNIVERSITY   (South Africa)

^e NATIONAL INSTITUTE FOR COMMUNICABLE DISEASES   (South Africa)

Author keywords

Diphtheria vaccine; Haemophilus influenzae type b conjugate vaccine; Hepatitis B vaccine; HIV exposed uninfected; HIV infected; Pertussis vaccine; Tetanus vaccine

Indexed keywords

ANTIBODY; COMBACT HIB; DIPHTHERIA ANTIBODY; DIPHTHERIA PERTUSSIS TETANUS HAEMOPHILUS INFLUENZAE TYPE B VACCINE; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; PERTUSSIS TOXIN ANTIBODY; PNEUMOCOCCUS VACCINE; POLIOMYELITIS VACCINE; PREVNAR 7; TETANUS ANTIBODY; UNCLASSIFIED DRUG;

ANTIBODY RESPONSE; ARTICLE; CD4+ T LYMPHOCYTE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; INFANT; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

ANTI-RETROVIRAL AGENTS; ANTIBODIES, BACTERIAL; DIPHTHERIA-TETANUS-PERTUSSIS VACCINE; FEMALE; HAEMOPHILUS VACCINES; HEPATITIS B ANTIBODIES; HEPATITIS B VACCINES; HIV INFECTIONS; HUMANS; IMMUNOASSAY; INFANT; MALE;

EID: 84893246030     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0000000000000127     Document Type: Article

References (46)

1. Resino S, Galan I, Perez A, Leon JA, Seoane E, Gurbindo D, et al. HIV infected children with moderate/severe immune-suppression: Changes in the immune system after highly active antiretroviral therapy. Clin Exp Immunol 2004; 137:570-577.
2. Letvin NL, Walker BD. Immunopathogenesis and immunotherapy in AIDS virus infection. Nat Med 2003; 9:861-866.
3. Palumbo P, Hoyt L, Demasio K, Oleske J, Connor E. Population based study on measles and measles immunization in human immunodeficiency virus infected children. Pediat Infect Dis J 1992; 11:1008-1014.
4. Borkowsky W, Rigaud M, Krasinski K, Moore T, Lawrence R, Pollack H. Cell mediated and humoral immune responses in children infected with human immunodeficiency virus during the first four years of life. J Pediat 1992; 120:371-375.
5. Lane HC, Masur H, Edgar LC, Whalen G, Rook AH, Fauci AS. Abnormalities of B-cell activation and immunoregulation in patients with acquired immunodeficiency syndrome. N Engl J Med 1983; 309:453-458.
6. Shearer WT, Easley KA, Goldfarb J, Rosenblatt HM, Jenson HB, Kovacs A, et al. Prospective 5-year study of peripheral blood CD4, CD8, and CD19/CD20 lymphocytes and serum Igs in children born to HIV-1 mothers. J Allerg Clin Immunol 2000; 106:559-566.
7. Pensieroso S, Cagigi A, Palma P, Nilsson A, Capponi C, Freda E, et al. Timing of HAART defines the integrity of memory B cells and the longevity of humoral responses in HIV-1 verticallyinfected children. Proc Natl Acad Sci 2009; 106:7939-7944.
8. al-Attar I, Reisman J, Muehlmann M, McIntosh K. Decline of measles antibody titers after immunization in human immunodeficiency virus-infected children. Pediatr Infect Dis J 1995; 14:149-151.
9. Violari A, Cotton MF, Gibb DM, Babiker AG, Steyn J, Madhi SA, et al. Early antiretroviral therapy and mortality among HIVinfected infants. N Engl J Med 2008; 359:2233-2244.
10. Melvin AJ, Mohan KM. Response to immunization with measles, tetanus and Haemophilus influenzae type b vaccines in children who have human immunodeficiency virus type 1 and are treated with highly active antiretroviral therapy. Pediatrics 2003; 111:641-644.
11. Valdez H. Immune restoration after treatment of HIV-1 infection with highly active antiretroviral therapy (HAART). AIDS Rev 2002; 4:157-164.
12. Obaro SK, Pungatch D, Luzuruago K. Immunogenicity and efficacy of childhood vaccines in HIV-1 infected children. Lancet 2004; 4:510-518.
13. Madhi SA, Adrian P, Cotton MF, McIntyre JA, Jean-Philippe P, Meadows S, et al. Effect of HIV infection status and antiretroviral treatment on quantitative and qualitative antibody responses to pneumococcal conjugate vaccine in infants. J Infect Dis 2010; 202:355-361.
14. Simani OE, Adrian PV, Violari A, Kuwanda L, Otwembe K, Nunes M, et al. Effect of in-utero HIV exposure and antiretroviral treatment strategies on measles susceptibility and immunogenicity of measles-vaccine. AIDS 2013; 27:1583-1591.
15. Chuachoowong R, Shaffer N, Siriwasin W, Chaisilwattana P, Young NL, Mock PA, et al. Short course antenatal zidovudine reduces both cervicovaginal human immunodeficiency virus type 1 RNA levels and risk of perinatal transmission. J Infect Dis 2000; 181:99-106.
16. Connor EM, Sperling RS, Gelber R, Kiselev P, Scott G, OSullivan MJ, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. N Engl J Med 1994; 331:1173-1180.
17. Kind C, Rudin C, Siegrist C, Wyler CA, Biedermann K, Lauper U, et al. Prevention of vertical HIV infection: Additive protective effect of elective cesarean section and zidovudine prophalaxis. AIDS 1998; 12:205-210.
18. Simonds RJ, Steketee R, Nesheim P, Matheson P, Palumbo P, Algeret L, et al. Impact of zidovudine use on risk and risk factors for perinatal transmission of HIV. AIDS 1998; 12:301-308.
19. Newell ML, Coovadia H, Cortina-Borja M, Rollins N, Gaillard P, Dabis F, et al. Mortality of infected and uninfected infants born to HIV-infected mothers in Africa: A pooled analysis. Lancet 2004; 364:1236-1243.
20. Koyanagi A, Humphrey JH, Ntozini R, Nathoo K, Moulton LH, Iliff P, et al. Morbidity among human immunodeficiency virusexposed but uninfected, human immunodeficiency virus-infected, and human immunodeficiency virus-unexposed infants in Zimbabwe before availability of highly active antiretroviral therapy. Pediatr Infect Dis J 2011; 30:45-51.
21. Hygino J, Lima PG, Filho RGS, Silva AAL, Saramago CSM, Andrade RGM, et al. Altered immunological reactivity in HIV-1-exposed uninfected neonates. Clin Immunol 2008; 127:340-347.
22. Faye A, Pornprasert S, Mary JY, Dolcini G, Derrien M, Barré-Sinoussi F, et al. Characterization of the main placental cytokine profiles from HIV-1-infected pregnant women treated with antiretroviral drugs in France. Clin Exp Immunol 2007; 149:430-439.
23. Bunders M, Thorne C, Newell ML. Maternal and infant factors and lymphocyte, CD4 and CD8 cell counts in uninfected children of HIV-1-infected mothers. AIDS 2005; 19:1071-1079.
24. Clerici M, Saresella M, Colombo F, Fossati S, Sala N, Bricalli D, et al. T-lymphocyte maturation abnormalities in uninfected newborns and children with vertical exposure to HIV. Blood 2000; 96:3866-3871.
25. Gesner M, Papaevangelou V, Kim M, Chen S, Moore T, Krasinski K, et al. Alteration in the proportion of CD4 T lymphocytes in a subgroup of human immunodefiency virusexposed-uninfected children. Pediatrics 1994; 93:624-630.
26. Neilsen SD, Jeppesen DL, Kolte L, Clark DR, Sorensen TU, Dreves A, et al. Impaired progenator cell function in HIVnegative infants of HIV-positive mothers results in decreased thymic output and low CD4 counts. Blood 2001; 98:398-404.
27. Feiterna-Sperling C, Weizsaecker K, Buhrer C, Casteleyn S, Loui A, Schmitz T, et al. Hematologic effects of maternal antiretroviral therapy and transmission prophylaxis in HIV-1-exposed uninfected newborn infants. JAIDS 2007; 45:43-51.
28. Borges-Almeida E, Milanez HMBM, Vilela MMS, Cunha FGP, Abramczuk BM, Reis-Alves SC, et al. The impact of maternal HIV infection on cord blood lymphocyte subsets and cytokine profile in exposed noninfected newborns.BMC Infect Dis 2011; 11:38-48.
29. Van Rie A, Madhi SA, Heera JR, Meddows-Taylor S, Wendelboe AM, Anthony F, et al. Gamma inteferon production in response to Mycobacterium bovis BCG and Mycobacterium tuberculosis antigens in infants born to human immunodeficiency virusinfected mothers. Clin Vaccine Immunol 2006; 13:246-252.
30. Mahomed H, Kibel M, Hawkridge T, Schaaf HS, Hanekom WA, Iloni K, et al. The impact of a change in Bacille Calmette-Guérin vaccine policy on tuberculosis incidence in children in Cape Town, South Africa. Pediatr Infect Dis J 2006; 25:1167-1172.
31. Jones CE, Naidoo S, De Beer C, Esser M, Kampmann B, Hesseling AC. Maternal HIV infection and antibody responses against vaccine-preventable diseases in uninfected infants. JAMA 2011; 305:576-584.
32. Abramczuk BM, Mazzola TN, Moreno YM, Zorzeto TQ, Quintilio W, Wolf PS, et al. Impaired humoral response to vaccines among HIV-exposed uninfected infants. Clin Vaccine Immunol 2011; 18:1406-1409.
33. Kurikka S, Kayhty H, Saarrinen L, Ronnberg PR, Eskola J, Makela PH. Immunologic priming by one dose of Haemophilus influenzae type b conjugate vaccine in infancy. J Infect Dis 1995; 172:1268-1272.
34. Romero-Steiner S, XXX FJ, Biltoft C, Wohl ME, Sanchez J, Feris J, et al. Functional antibody activity elicited by fractional doses of Haemophilus influenzae type b conjugate vaccine (polyribosylribitol phosphate-tetanus toxoid conjugate). Clin Diag Lab Immunol 2001; 8:1115-1119.
35. Schlesinger Y, Granoff DM. Avidity and bactericidal activity of antibody elicited by different Haemophilus influenzae type b conjugate vaccine. JAMA 1992; 267:1489-1494.
36. Plotkin SA. Correlates of protection induced by vaccination. Clin Vacc Immunol 2010; 17:1055-1065.
37. WHO. Antiretroviral therapy for HIV infection in infants and children: Towards universal access: Recommendations for a Public Health approach: 2010 Revision. Geneva: World Health Organization; 2010.
38. Sutcliffe CG, Moss WJ. Do children infected with HIV receiving HAART need to be re-vaccinated Lancet Infect Dis 2010; 10:630-642.
39. Madhi SA, Peterson K, Khoosal M, Huebner RE, Mbelle N, Mothupi R, et al. Reduced effectiveness of Haemophilus influenzae type b conjugate vaccine in children with high prevalence of human immunodeficiency virus type 1 infection. Pediatr Infect Dis 2002; 21:315-321.
40. Peters VB, Sood SK. Immunity to Haemophilus influenzae type b after reimmunization with oligosaccharide CRM197 conjugate vaccine in children with human immunodeficiency virus infection. Pediatr Infect Dis J 1997; 16:711-713.
41. Rustein RM, Rudy BJ, Cnaan A. Response of human immunodeficiency virus-exposed and infected infants to Haemophilus influenzae type b conjugate vaccine. Arch Pediatr Adolesc Med 1996; 150:838-841.
42. Scott S, Moss WJ, Cousens S, Beeler JA, Audet SA, Mugala N, et al. The influence of HIV-1 exposure and infection on levels of passively acquired antibodies to measles virus in Zambian infants. Clin Infect Dis 2007; 45:1417-1424.
43. Montoya CJ, Toro MF, Aguirre C, Bustamante A, Hernandez M, Aranggo LP, et al. Abnormal humoral immune response to influenza vaccination in pediatric type-1 human immunodeficiency virus infected patients receiving highly active antiretroviral therapy. MemInst Oswaldo Cruz 2007; 102:501-508.
44. Miyamoto M, Pessoa SD, Ono E, Machado DM, Salomao R, Succi RC, et al. Low CD4R T-cell levels and B-cell apoptosis in vertically exposed noninfected children and adolescents. J Trop Pediat 2010; 56:427-432.
45. Rieke BA, Naidoo S, Ruck CE, Slogrove AL, De Beer C, La Grange L, et al. Antibody responses to vaccination among South African HIV-exposed and uninfected infants during the first 2 years of life. Clin Vaccine Immunol 2013; 20:33-38.
46. Vermaak A, Theron GB, Schubert PT, Kidd M, Rabie U, Adjiba BM, et al. Morphologic changes in the placentas of HIV-positive women and their association with degree of immune suppression. Int J Gynecol Obst 2012; 119:239-243.